Analyst Price Targets — AGIO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 30, 2026 4:38 pm | — | H.C. Wainwright | $55.00 | $32.93 | TheFly | Agios Pharmaceuticals price target raised to $55 from $52 at H.C. Wainwright |
| July 21, 2026 3:00 pm | Emily Bodnar | H.C. Wainwright | $52.00 | $37.77 | TheFly | Agios Pharmaceuticals price target lowered to $52 from $54 at H.C. Wainwright |
| July 7, 2026 1:14 pm | — | Truist Financial | $41.00 | $42.07 | TheFly | Agios Pharmaceuticals price target raised to $41 from $36 at Truist |
| July 7, 2026 11:27 am | — | RBC Capital | $32.00 | $37.39 | TheFly | Agios Pharmaceuticals price target raised to $32 from $28 at RBC Capital |
| June 15, 2026 10:49 am | Emily Bodnar | H.C. Wainwright | $54.00 | $29.46 | StreetInsider | Agios Pharma (AGIO) PT Raised to $54 at H.C. Wainwright |
| April 30, 2026 11:35 am | — | Truist Financial | $36.00 | $28.05 | TheFly | Agios Pharmaceuticals price target lowered to $36 from $39 at Truist |
| April 20, 2026 4:07 pm | Emily Bodnar | H.C. Wainwright | $50.00 | $26.93 | TheFly | H.C. Wainwright cuts Agios target on smaller market post Novo data |
| February 12, 2026 4:40 pm | Greg Renza | Truist Financial | $39.00 | $28.42 | StreetInsider | Agios Pharma (AGIO) PT Raised to $39 at Truist Securities |
| December 26, 2025 11:26 am | — | Leerink Partners | $40.00 | $29.17 | TheFly | Agios Pharmaceuticals price target raised to $40 from $34 at Leerink |
| December 24, 2025 5:29 pm | — | H.C. Wainwright | $62.00 | $29.17 | TheFly | Agios Pharmaceuticals price target raised to $62 from $48 at H.C. Wainwright |
Latest News for AGIO
Agios is leveraging mitapivat's commercial platform across PK deficiency, thalassemia, and potentially sickle cell disease to build a durable rare-disease franchise. Thalassemia launch drove Q2 2026 mitapivat revenue to $44.7M, up 259% YoY, with strong payer coverage and operational leverage emerging. AGIO's $965M cash position supports pipeline expansion and mitigates near-term dilution risk ahead of the November…
NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Assenagon Asset Management S.A. lifted its stake in Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) by 54.8% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 103,955 shares of the biopharmaceutical company's stock after acquiring an additional 36,802 shares during the quarter. Assenagon
NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (NASDAQ: AGIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AGIO.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.